{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:30:52Z","timestamp":1792265452699,"version":"4.4.0"},"reference-count":38,"publisher":"American Association for Cancer Research (AACR)","issue":"1","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Because of its amplification and\/or overexpression in many human tumors, the HER-2\/neu proto-oncogene represents an attractive target for T-cell-mediated vaccination strategies. However, overexpression of oncogenes is often associated with defective expression of components of the MHC class I antigen-processing machinery (APM), thereby resulting in an immune escape phenotype of oncogene-transformed cells. To determine whether HER-2\/neu influences the MHC class I antigen-processing pathway, the expression pattern of different APM components was examined in murine in vitro models of constitutive and tetracycline-controlled HER-2\/neu expression. In comparison with HER-2\/neu\u2212 control cells, HER-2\/neu+ fibroblasts exhibit reduced levels of MHC class I surface antigens that were associated with impaired expression and\/or function of the peptide transporter associated with antigen processing, the proteasome subunits low molecular weight protein 2 and low molecular weight protein 10, the proteasome activators PA28\u03b1 and PA28\u03b2, and tapasin. These APM abnormalities resulted in reduced sensitivity to lysis by CTLs. The HER-2\/neu-mediated immune escape phenotype could be corrected by IFN-\u03b3 treatment. The clinical relevance of this finding was supported by an inverse correlation between HER-2\/neu and the peptide transporter associated with antigen-processing protein expression as determined by immunhistochemical analysis of a series of HER-2\/neu\u2212 and HER-2\/neu+ breast cancer specimens. Thus, a functional link between deficient APM component expression and HER-2\/neu overexpression is proposed that might influence the design of HER-2\/neu-targeted T-cell-based immunotherapeutic strategies.<\/jats:p>","DOI":"10.1158\/0008-5472.can-2522-2","type":"journal-article","created":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T22:35:47Z","timestamp":1127255747000},"page":"215-220","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":110,"title":["HER-2\/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway"],"prefix":"10.1158","volume":"64","author":[{"given":"Felix","family":"Herrmann","sequence":"first","affiliation":[{"name":"1Third Department of Internal Medicine and"},{"name":"5Institute of Virology, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Anton","family":"Lehr","sequence":"additional","affiliation":[{"name":"2Pathology, Johannes Gutenberg-University, Mainz;"},{"name":"5Institute of Virology, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Drexler","sequence":"additional","affiliation":[{"name":"4Gesellschaft fu\u0308r Umwelt und Gesundheit GmbH-Institute for Molecular Virology and"},{"name":"5Institute of Virology, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Sutter","sequence":"additional","affiliation":[{"name":"4Gesellschaft fu\u0308r Umwelt und Gesundheit GmbH-Institute for Molecular Virology and"},{"name":"5Institute of Virology, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hengstler","sequence":"additional","affiliation":[{"name":"3Institute of Toxicology, University of Mainz, Mainz; and"},{"name":"5Institute of Virology, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Wollscheid","sequence":"additional","affiliation":[{"name":"1Third Department of Internal Medicine and"},{"name":"5Institute of Virology, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Seliger","sequence":"additional","affiliation":[{"name":"1Third Department of Internal Medicine and"},{"name":"5Institute of Virology, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2004,1,16]]},"reference":[{"key":"2022061620093010000_B1","doi-asserted-by":"crossref","unstructured":"Goodenow R., Vogel J., Linsk R. Histocompatibility antigens on murine tumors. Science (Wash. DC), 230:\u2008777-783, \u20081985.","DOI":"10.1126\/science.2997918"},{"key":"2022061620093010000_B2","doi-asserted-by":"crossref","unstructured":"Garrido F., Ruiz-Cabello F., Cabrera T., Perez-Villar J. J., Lopez-Botet M., Duggan-Keen M., Stern P. L. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today, 18:\u200889-95, \u20081997.","DOI":"10.1016\/S0167-5699(96)10075-X"},{"key":"2022061620093010000_B3","doi-asserted-by":"crossref","unstructured":"Ferrone S., Marincola F. M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today, 16:\u2008487-494, \u20081995.","DOI":"10.1016\/0167-5699(95)80033-6"},{"key":"2022061620093010000_B4","doi-asserted-by":"crossref","unstructured":"Mausdley D. J., Pond J. S. Modulation of MHC antigen expression by viruses and oncogenes. Immunol. Today, 12:\u2008429-431, \u20081991.","DOI":"10.1016\/0167-5699(91)90013-J"},{"key":"2022061620093010000_B5","doi-asserted-by":"crossref","unstructured":"Seliger B., Harders C., Lohmann S., Momburg F., Urlinger S., Tampe\u0301 R., Huber C. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur. J. Immunol., 28:\u2008122-133, \u20081998.","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<122::AID-IMMU122>3.0.CO;2-F"},{"key":"2022061620093010000_B6","unstructured":"Seliger B., Harders C., Wollscheid U., Staege M. S., Reske-Kunz A. B., Huber C. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes. Exp. Hematol., 24:\u20081275-1279, \u20081996."},{"key":"2022061620093010000_B7","doi-asserted-by":"crossref","unstructured":"Seliger B., Maeurer M. J., Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today, 21:\u2008455-464, \u20082000.","DOI":"10.1016\/S0167-5699(00)01692-3"},{"key":"2022061620093010000_B8","doi-asserted-by":"crossref","unstructured":"Seliger B., Schreiber K., Delp K., Meissner M., Hammers S., Reichert T., Pawlischko K., Tampe R., Huber C. Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines. Tissue Antigens, 57:\u200839-45, \u20082001.","DOI":"10.1034\/j.1399-0039.2001.057001039.x"},{"key":"2022061620093010000_B9","unstructured":"Qin Z., Harders C., Cao X., Huber C., Blankenstein T., Seliger B. Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors. Cancer Res., 62:\u20082856-2860, \u20082002."},{"key":"2022061620093010000_B10","doi-asserted-by":"crossref","unstructured":"Hunter T. Oncoprotein networks. Cell, 88:\u2008333-346, \u20081997.","DOI":"10.1016\/S0092-8674(00)81872-3"},{"key":"2022061620093010000_B11","doi-asserted-by":"crossref","unstructured":"Lowy D. R., Willumsen B. M. Function and regulation of Ras. Annu. Rev. Biochem., 62:\u2008851-891, \u20081993.","DOI":"10.1146\/annurev.bi.62.070193.004223"},{"key":"2022061620093010000_B12","doi-asserted-by":"crossref","unstructured":"Paumelle R., Tulasne D., Kherrouche Z., Plaza S., Leroy C., Reveneau S., Vandenbunder B., Fafeur V., Tulashe D., Reveneau S. Hepatocyte growth factor\/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene, 21:\u20082309-2319, \u20082002.","DOI":"10.1038\/sj.onc.1205297"},{"key":"2022061620093010000_B13","unstructured":"Norgaard P., Law B., Joseph H., Page D. L., Shyr Y., Mays D., Pietenpol J. A., Kohl N. E., Oliff A., Coffey R. J., Jr., Poulsen H. S., Moses H. L. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) \u03b1 and TGF \u03b1\/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin. Cancer Res., 5:\u200835-42, \u20081999."},{"key":"2022061620093010000_B14","doi-asserted-by":"crossref","unstructured":"Sivaraman V. S., Wang H., Nuovo G. J., Malbon C. C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Investig., 99:\u20081478-1483, \u20081997.","DOI":"10.1172\/JCI119309"},{"key":"2022061620093010000_B15","doi-asserted-by":"crossref","unstructured":"Coussens L., Yang-Feng T. L., Liao Y. C., Chen E., Gray A., McGrath J., Seeburg P. H., Libermann T. A., Schlessinger J., Francke U., Levinson A., Ulrich A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (Wash. DC), 230:\u20081132-1139, \u20081985.","DOI":"10.1126\/science.2999974"},{"key":"2022061620093010000_B16","unstructured":"Press M. F., Cordon-Cardo C., Slamon D. J. Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues. Oncogene, 5:\u2008953-962, \u20081990."},{"key":"2022061620093010000_B17","doi-asserted-by":"crossref","unstructured":"Slamon D. J., Godolphin W., Jones L. A., Hilt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ulrich A., Press M. F. Studies of the HER-2\/neu protooncogene in human breast and ovarian cancer. Science (Wash. DC), 244:\u2008707-712, \u20081989.","DOI":"10.1126\/science.2470152"},{"key":"2022061620093010000_B18","doi-asserted-by":"crossref","unstructured":"Seshadri R., Firgaira F. A., Horsfall D. J., McCaul K., Setlur V., Kitchen P. Clinical significance of HER-2\/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J. Clin. Oncol., 11:\u20081936-1942, \u20081993.","DOI":"10.1200\/JCO.1993.11.10.1936"},{"key":"2022061620093010000_B19","doi-asserted-by":"crossref","unstructured":"Pegram M. D., Lipton A., Hayes D. F., Weber B. L., Baselga J. M., Tripathy D., Baly D., Baughman S. A., Twaddell T., Glaspy J. A., Slamon D. J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2\/neu monoclonal antibody plus cisplatin in patients with HER2\/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol., 16:\u20082659-2671, \u20081998.","DOI":"10.1200\/JCO.1998.16.8.2659"},{"key":"2022061620093010000_B20","unstructured":"Murray J. L., Przepiorka D., Ioannides C. G. Clinical trials of HER-2\/neu specific vaccines. Semin. Oncol., 27:\u200871-75, \u20082000."},{"key":"2022061620093010000_B21","unstructured":"Baselga J., Norton L., Albanell J., Kim Y. M., Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2\/neu overexpressing human breast cancer xenografts. Cancer Res., 58:\u20082825-2831, \u20081998."},{"key":"2022061620093010000_B22","doi-asserted-by":"crossref","unstructured":"Disis M., Cheever M. HER-2\/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv. Cancer Res., 71:\u2008343-371, \u20081997.","DOI":"10.1016\/S0065-230X(08)60103-7"},{"key":"2022061620093010000_B23","unstructured":"Reilly R. T., Machiels J. P., Emens L. A., Ercolini A. M., Okoye F. I., Lei R. Y., Weintraub D., Jaffee E. M. The collaboration of both humoral and cellular HER-2\/neu targeted immune responses is required for the complete eradication of HER-2\/neu expressing tumors. Cancer Res., 61:\u2008880-883, \u20082001."},{"key":"2022061620093010000_B24","doi-asserted-by":"crossref","unstructured":"Knutson K. L., Schiffman K., Disis M. L. Immunization with a HER-2\/neu helper peptide vaccine generates HER-2\/neu CD8 T cell immunity in cancer patients. J. Clin. Investig., 107:\u2008477-484, \u20082001.","DOI":"10.1172\/JCI11752"},{"key":"2022061620093010000_B25","doi-asserted-by":"crossref","unstructured":"Lollini P. L., Nicoletti G., Landuzzi L., De Giovanni C., Rossi I., Di Carlo E., Musiani P., Nanni P. Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2\/neu transgenic mice. Int. J. Cancer, 77:\u2008937-941, \u20081998.","DOI":"10.1002\/(SICI)1097-0215(19980911)77:6<937::AID-IJC24>3.0.CO;2-X"},{"key":"2022061620093010000_B26","doi-asserted-by":"crossref","unstructured":"Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA, 89:\u20085547-5551, \u20081992.","DOI":"10.1073\/pnas.89.12.5547"},{"key":"2022061620093010000_B27","unstructured":"Baasner S., von Melchner H., Klenner T., Hilgard P., Beckers T. Reversible tumorigenesis in mice by conditional expression of the HER2\/c-erbB2 receptor tyrosine kinase. Oncogene, 13:\u2008901-911, \u20081996."},{"key":"2022061620093010000_B28","doi-asserted-by":"crossref","unstructured":"Wo\u0308lfel T., van Pel A., Brichard V., Schneider J., Seliger B., Meyer zum Bu\u0308schenfelde K. H., Boon T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol., 24:\u2008759-764, \u20081994.","DOI":"10.1002\/eji.1830240340"},{"key":"2022061620093010000_B29","doi-asserted-by":"crossref","unstructured":"Seliger B., Wollscheid U., Momburg F., Blankenstein T., Huber C. Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. Tissue Antigens, 56:\u2008327-336, \u20082000.","DOI":"10.1034\/j.1399-0039.2000.560404.x"},{"key":"2022061620093010000_B30","doi-asserted-by":"crossref","unstructured":"Bordier C. Phase separation of integral membrane proteins in Triton X-114 solution. J. Biochem., 256:\u20081604-1607, \u20081981.","DOI":"10.1016\/S0021-9258(19)69848-0"},{"key":"2022061620093010000_B31","doi-asserted-by":"crossref","unstructured":"Neefjes J. J., Momburg F., Ha\u0308mmerling G. J. Selective and ATP-dependent translocation of peptides by MHC-encoded transporter. Science (Wash. DC), 261:\u2008769-771, \u20081993.","DOI":"10.1126\/science.8342042"},{"key":"2022061620093010000_B32","doi-asserted-by":"crossref","unstructured":"Wo\u0308lfel T., Schneider J., Meyer Zum Buschenfelde K. H., Rammensee H. G., Rotzschke O., Falk K. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1. Int. J. Cancer, 57:\u2008413-418, \u20081994.","DOI":"10.1002\/ijc.2910570320"},{"key":"2022061620093010000_B33","unstructured":"Drexler I., Antunes E., Schmitz M., Wo\u0308lfel T., Huber C., Erfle V., Rieber P., Theobald M., Sutter G. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res., 59:\u20084955-4963, \u20081999."},{"key":"2022061620093010000_B34","doi-asserted-by":"crossref","unstructured":"Meyer T. H., van Endert P. M., Uebel S., Ehring B., Tampe R. Functional expression and purification of the ABC transporter complex associated with antigen processing (TAP) in insect cells. FEBS Lett., 351:\u2008443-447, \u20081994.","DOI":"10.1016\/0014-5793(94)00908-2"},{"key":"2022061620093010000_B35","doi-asserted-by":"crossref","unstructured":"van Endert P. T., Tampe\u0301 R., Meyer T. H., Tisch R., Bach J. F., McDewitt H. O. A sequential model for peptide binding and transport by the transporters associated with antigen processing. Immunity, 1:\u2008491-500, \u20081994.","DOI":"10.1016\/1074-7613(94)90091-4"},{"key":"2022061620093010000_B36","doi-asserted-by":"crossref","unstructured":"Castilleja A., Ward N. E., O\u2019Brian C. A., Swearingen B., II, Swan E., Gillogly M. A., Murray J. L., Kudelka A. P., Gershenson D. M., Ionannides C. G. Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL: implications for tumor immunogenicity. Mol. Cell. Biochem., 217:\u200821-33, \u20082001.","DOI":"10.1023\/A:1007267814251"},{"key":"2022061620093010000_B37","doi-asserted-by":"crossref","unstructured":"Nijman H. W., van Diest P. J., Poort-Keesom K. J., von Mensdorff-Pouilly S., Vertraeten R. A., Kummer A., Meijer C. J., Melief C. J., Hilgers J., Keenemans P. T cell infiltration and MHC class I and class II expression in the presence of tumor antigens: an immunohistochemical study in patients with serous epithelial ovarian cancer. Eur. J. Obstet. Gynecol. Reprod. Biol., 94:\u2008114-120, \u20082001.","DOI":"10.1016\/S0301-2115(00)00294-3"},{"key":"2022061620093010000_B38","doi-asserted-by":"crossref","unstructured":"Lohmann S., Wollscheid U., Huber C., Seliger B. Multiple levels of MHC class I downregulation by ras oncogenes. Scand. J. Immunol., 43:\u2008537-544, \u20081996.","DOI":"10.1046\/j.1365-3083.1996.d01-73.x"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/64\/1\/215\/2514555\/zch00104000215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/64\/1\/215\/2514555\/zch00104000215.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T20:15:21Z","timestamp":1655410521000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/64\/1\/215\/511279\/HER-2-neu-Mediated-Regulation-of-Components-of-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2004,1,16]]},"published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-2522-2","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,1]]}}}